Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861758 | 1.00 | SYK (0.47) | SYKJAK3BTKENPP1MAPK8 | |
| SCHEMBL15142858 | 0.84 | SYK (0.47) | SYKJAK3BTKARGSK3B | |
| SCHEMBL18185851 | 0.82 | MAPK8 (0.43) | SYKENPP1MAPK8MAPK9GSK3B | |
| SCHEMBL22931760 | 0.81 | SYK (0.51) | SYKJAK3BTKARGSK3B | |
| SCHEMBL14861638 | 0.77 | PDCD1 (0.41) | SYKGSK3BDYRK1AATRMAPKAPK2 | |
| SCHEMBL30140938 | 0.77 | PDCD1 (0.41) | SYKGSK3BDYRK1AATRMAPKAPK2 | |
| SCHEMBL19002319 | 0.76 | GSK3B (0.39) | SYKGSK3BDYRK1AATRMAPKAPK2 | |
| SCHEMBL20106531 | 0.74 | CHEK1 (0.40) | MAPK8MAPK9CHEK1MAP4K1KCNH2 | |
| SCHEMBL31709542 | 0.71 | SYK (0.38) | SYKGSK3BDYRK1AATREGLN2 | |
| SCHEMBL22931761 | 0.71 | FLT3 (0.39) | SYKARCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | SYK 3853/4885JAK3 942/4885BTK 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.